Welcome to CSNpharm! For Research Use Only!
Home +1-708-781-1677 sales@csnpharm.com    

c-Met/HGFR

c-Met/HGFR

Cat. No. Product Name CAS No. Information
CSN17399 Tyrosine Kinase Inhibitor 1021950-26-4 Tyrosine kinase inhibitor is a drug used for advanced renal cell carcinoma
CSN12917 Tivantinib 905854-02-6 Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0355 M with little activity to Ron and no inhibition to EGFR InsR PDGFR or FGFR14
CSN15875 Tepotinib   1100598-32-0 Tepotinib is a selective c-Met inhibitor with IC50 value of 3nM, over 200-fold against IRAK4, TrkA, Axl, IRAK1, Mer, TrkB and Ron.
CSN16106 SGX-523   1022150-57-7 SGX-523 is a potent and selective c-Met inhibitor with IC50 of 4 nM
CSN25214 SCR-1481B1 x(NH2(OH)3) N/A SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor.
CSN17517 SCR-1481B1 1174161-86-4 SCR-1481B1 is a potent compound that has activity against cancers dependent upon Met activation and also has activity against cancers as a VEGFR inhibitor
CSN17684 Savolitinib 1313725-88-0 Savolitinib is an orally bioavailable inhibitor of the c-Met receptor tyrosine kinase (IC50 5 nM) with potential antineoplastic activity.
CSN20348 SAR125844 1116743-46-4 SAR125844 is a potent and highly selective c-Met inhibitor with potential antineoplastic activity
CSN19153 S49076 1265965-22-7 S49076 is a potent inhibitor of MET AXLMER and FGFRs
CSN22605 S49076 HCl 1265966-31-1 S49076 hydrochloride is a potent, ATP-competitive tyrosine kinase inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 <20 nM.
CSN12934 PHA-665752 477575-56-7 PHA-665752 is a potent selective and ATP-competitive c-Met inhibitor with IC50 of 9 nM
CSN18635 PF-04217903 Methanesulfonate 956906-93-7 PF-04217903 Methanesulfonate is a highlu selective c-Met inhibitor with IC50 of 48 nM
CSN16129 PF-04217903 956905-27-4 PF-04217903 is a selective ATP-competitive c-Met inhibitor with IC50 of 48 nM susceptible to oncogenic mutations no activity to Y1230C mutant
CSN17159 NVP-BVU972 1185763-69-2 NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects
CSN23572 Norcantharidin 29745-04-8 Norcantharidin is a potential antitumor agent.
CSN23685 Ningetinib Tosylate 1394820-77-9 Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor TKI and the IC50 for c-Met VEGFR2 and Axl are 67 nM 19 nM and 10 nM respectively
CSN24062 NIngetinib 1394820-69-9 Ningetinib is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively.
CSN17658 MK-8033 HCl 1283000-43-0 MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.
CSN13613 MK-8033 1001917-37-8 MK-8033 is a specific dual ATP competitive c-MetRon inhibitor IC501 nM Wt c-Met under investigation as a treatment for cancer
CSN16566 MK-2461 917879-39-1 MK-2461 is a potent and multi-targeted inhibitor for c-Met with IC50 of 04-25 nM also inhibits FGFR123 KDR TrkAB and Flt4 with IC50 of 653950 nM 44 nM 4661 nM and 78 nM respectively
CSN13734 Merestinib 1206799-15-6 LY2801653 is a potent and orally bioavailable inhibitor of c-MET kinase with Ki of 2 nM
CSN17560 LY2801653 2HCl 1206801-37-7 LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase (Ki= 2 nM).
CSN22436 JNJ-38877618 943540-74-7 JNJ-38877618 is a potent highly selective orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met respectively
CSN12936 JNJ-38877605 943540-75-8 JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM
CSN15776 INC28060 1029712-80-8 INCB28060 is a potent and selective c-MET kinase inhibitor. INCB28060 inhibits c-MET kinase activity with an average IC50 of 0.13 nM.
CSN19988 Herbacetin 527-95-7 Herbacetin, a natural product isolated and purified from the herbs of Equisetum hyemale L., induces HepG2 apoptosis in a ROS-mediated mitochondria-dependent manner that correlate with the inactivation of the PI3K/Akt pathway, exerts an anti-inflammatory effect through suppression of LPS-induced JNK and NF-κB signaling pathways and diminished production of proinflammatory cytokines and mediators, and is a Met inhibitor with a potential utility in cancer therapeutics, suppresses the HGF-induced motility of human breast cancer MDA-MB-231 cells by inhibiting c-Met and Akt phosphorylation.
CSN15829 Golvatinib 928037-13-2 Golvatinib is a dual c-Met and VEGFR-2 inhibitor with IC50 of 14 nM and 16 nM
CSN24153 Glumetinib 1642581-63-2 Glumetinib is a novel, potent and highly selective inhibitor of c-Met.
CSN17479 Glesatinib HCl 1123838-51-6 Glesatinib HCl is an inhibitor of the MET and Axl receptor tyrosine kinase pathways, which drive tumour growth when altered.
CSN12685 Foretinib 849217-64-7 Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM in cell-free assays. Foretinib is less potent against Ron, Flt-134, Kit, PDGFR and Tie-2, and with little activity to FGFR1 and EGFR.
CSN22549 Ensartinib 1370651-20-9 Ensartinib is a novel potent anaplastic lymphoma kinase ALK small molecule tyrosine kinase inhibitor TKI with additional activity against MET ABL Axl EPHA2 LTK ROS1 and SLK ALK autophosphorylation is significantly diminished by X-396 albeit at higher concentrations required to block autophosphorylation of the wild-type fusion
CSN24316 Dihexa acetate N/A Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.
CSN24802 DBPR114 N/A DBPR114 is a potent multi-kinase inhibitor with potent activities against more than 57 oncogenic kinases, including Aurora-A, FLT3, CSF1R, MET, etc. DBPR114 exhibited favorable PK profiles: a long half-life (t1/2 = 23.5 h), moderate clearance and high volume of distribution. Also DBPR114 can effectively inhibit the growth of human acute myeloid leukemia MOLM-13 and MV4-11, MIA PaCa-2, Hep3B, MKN45, Colo205, and NTUB1 solid tumor xenografts in vivo without causing significant body weight loss.
CSN22378 c-Met-IN-2 1635406-73-3 c-Met-IN-2 is a potent selective and orally available c-Met inhibitor with an IC50 of 06 nM with antitumor activity
CSN16262 c-Met Inhibitor 1 1357072-61-7 c-Met Inhibitor 1 is a c-Met receptor signaling pathway inhibitor used for the treatment of cancer including gastric glioblastoma and pancreatic cancer
CSN23729 PLB-1001 1440964-89-5 Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily[1].
CSN16525 BMS-794833 1174046-72-0 BMS-794833 is a potent ATP competitive inhibitor of Met and VEGFR2 with IC50 of 17 and 15 nM
CSN13471 BMS-777607 1025720-94-8 BMS-777607 is a Met-related inhibitor for c-Met Axl Ron and Tyro3 with IC50 of 39 nM 11 nM 18 nM and 43 nM being 40-fold selective for Met-related targets versus Lck VEGFR-2 and TrkAB and more than 500-fold greater selectivity versus all other receptor and non receptor kinases
CSN25296 BAY 474 1033767-86-0 BAY 474 is a tyrosine-protein kinase c-Met inhibitor and a structural genomics consortium (SGC) epigenetics probe.
CSN17199 AMG-458 913376-83-7 AMG-458 is a potent c-Met inhibitor with Ki of 12 nM 350-fold selectivity for c-Met than VEGFR2 in cells
CSN17516 AMG-337 1173699-31-4 AMG-337 is a potent highly selective and ATP-competitive MET kinase inhibitor with an IC50 of 5nM in enzymatic assays
CSN16548 AMG-208 1002304-34-8 AMG-208 is a potent small molecular c-Met inhibitor with an IC50 of 93 nM
CSN16259 Altiratinib 1345847-93-9 Altiratinib is a c-METTIE-2VEGFR inhibitor which effectively reduce tumor burden in vivo and block c-MET pTyr1349-mediated signaling cell growth and migration as compared with a HGF antagonist in vitro
<< PREV 1 2 NEXT >>